About FibroBiologics, Inc. Common Stock
https://www.fibrobiologics.comFibroBiologics, Inc., a clinical-stage cell therapy company, develops and commercializes fibroblast-based therapies in the United States. It is developing CybroCell, for the treatment of degenerative disc disease; CYMS101 to treat multiple sclerosis; and CYWC628 for wound healing.
CEO
Peter O'Heeron
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 2 of 12
Ratings Snapshot
Rating : C-
Most Recent Analyst Grades
Grade Summary
Showing Top 2 of 2
Price Target
Institutional Ownership
VANGUARD GROUP INC
Shares:1.23M
Value:$436.14K
BLACKROCK INC.
Shares:918.96K
Value:$324.85K
YORKVILLE ADVISORS GLOBAL, LP
Shares:509.79K
Value:$180.21K
Summary
Showing Top 3 of 59
About FibroBiologics, Inc. Common Stock
https://www.fibrobiologics.comFibroBiologics, Inc., a clinical-stage cell therapy company, develops and commercializes fibroblast-based therapies in the United States. It is developing CybroCell, for the treatment of degenerative disc disease; CYMS101 to treat multiple sclerosis; and CYWC628 for wound healing.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $0 | $4.81M ▲ | $-5.78M ▼ | 0% | $-0.13 ▼ | $-5.55M ▼ |
| Q2-2025 | $0 | $4.49M ▼ | $-4.66M ▲ | 0% | $-0.12 ▲ | $-4.45M ▲ |
| Q1-2025 | $0 | $4.53M ▲ | $-4.97M ▼ | 0% | $-0.14 ▼ | $-4.8M ▼ |
| Q4-2024 | $0 | $3.71M ▲ | $-3.1M ▼ | 0% | $-0.09 ▼ | $-2.94M ▼ |
| Q3-2024 | $0 | $3.35M | $-500K | 0% | $-0.01 | $-352K |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $4.87M ▼ | $8.74M ▼ | $8.62M ▼ | $125K ▼ |
| Q2-2025 | $8.85M ▲ | $13.91M ▲ | $13.05M ▲ | $860K ▼ |
| Q1-2025 | $8.67M ▼ | $11.43M ▼ | $9.08M ▼ | $2.35M ▼ |
| Q4-2024 | $13.98M ▲ | $16.45M ▲ | $13.71M ▲ | $2.73M ▼ |
| Q3-2024 | $7.83M | $10.47M | $7.73M | $2.74M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-5.78M ▼ | $-3.97M ▲ | $-6K ▲ | $0 ▼ | $-3.98M ▼ | $-3.98M ▲ |
| Q2-2025 | $-4.66M ▲ | $-3.98M ▲ | $-213K ▼ | $4.38M ▲ | $178K ▲ | $-4.2M ▲ |
| Q1-2025 | $-4.97M ▼ | $-5.28M ▼ | $-43K ▲ | $0 ▼ | $-5.32M ▼ | $-5.32M ▼ |
| Q4-2024 | $-3.1M ▼ | $-3.07M ▼ | $-99K ▼ | $9.33M ▲ | $6.16M ▲ | $-3.17M ▼ |
| Q3-2024 | $-500K | $-2.61M | $-11K | $4.47M | $1.85M | $-2.62M |
CEO
Peter O'Heeron
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 2 of 12
Ratings Snapshot
Rating : C-
Most Recent Analyst Grades
Grade Summary
Showing Top 2 of 2
Price Target
Institutional Ownership
VANGUARD GROUP INC
Shares:1.23M
Value:$436.14K
BLACKROCK INC.
Shares:918.96K
Value:$324.85K
YORKVILLE ADVISORS GLOBAL, LP
Shares:509.79K
Value:$180.21K
Summary
Showing Top 3 of 59